Although both tests determine whether a tumor is a potential target for HER2-targeted therapy, almost 23 % of women with early breast cancer treated with trastuzumab-based chemotherapy relapse within the first 10 years of diagnosis [15]. This evidence concerns the gene ERBB2 and breast carcinoma.